Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 701–800 of 1,001
Perez-Belmonte, L. M., Ricci, M., Sanz‐Cánovas, J., Millán‐Gómez, M., Osuna‐Sánchez, J., Ruiz-Moreno, M. I., Bernal-López, M. R., Lopez-Carmona, M. D., Jiménez-Navarro, M. F., Gómez‐Doblas, J. J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163540 · Cited by 12
van Ruiten, C. C., Hesp, A. C., & van Raalte, D. H. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.03.031 · Cited by 11
Jhalani, N. B. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02169-3 · Cited by 14
“1a) [7, 10, 11, 19], and these differences most likely had an effect on the individual study results, but a consistent finding was a significant reduction in HHF compared with placebo [7, 10, 11, 19].”
BackgroundResultScheen, A. J. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2105693 · Cited by 13
Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise
Herring, R. A., Parsons, I., Shojaee‐Moradie, F., Stevenage, M., Jackson, N., MANDERS, R. J. F., Umpleby, A. M., Fielding, B. A., Davies, M. J., & Russell-Jones, D. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac617 · Cited by 10
Gao, L., Cheng, Z., Su, B., Su, X., Song, W., Guo, Y., Liao, L., Chen, X., Li, J., Tan, X., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14926 · Cited by 11
“In dedicated studies, some SGLT2 inhibitors have shown additional benefits including body weight loss and blood pressure reduction, as well as beneficial class effects on metabolic, cardiovascular and renal outcomes.(16-22) Janagliflozin is considered a novel, highly selective, oral SGLT2 inhibitor.”
BackgroundHsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 14
“03)), but significantly reduced the risk for first HHF by 30%, which was not influenced by previous HF [17,18].”
BackgroundDiabetes mellitus and heart disease
Chandrasekaran, P., & Weiskirchen, R. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.15 · Cited by 14
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
“Accordingly, SGLT2 inhibitors have additional cardiorenal effects in both people with and without T2D [80], including reduction in eGFR decline [81], progression to ESKD [82,83], cardiovascular and heart failure events and overall mortality [6,7,84].”
Self-citationMcMurray, J. J. V., Solomon, S. D., Lock, J. P., Massaro, J. M., Zhu, F., Zhou, W., Skali, H., Lewis, E. F., Freeman, M. W., & Halvorsen, Y. C. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15394 · Cited by 9
Keidai, Y., Yoshiji, S., Hasebe, M., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., & Inagaki, N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15122 · Cited by 13
Zuo, Q., He, L., Ma, S., Zhang, G., Zhai, J., Wang, Z., Zhang, T., Wang, Y., & Guo, Y. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0093 · Cited by 18
Sridhar, V. S., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Cater, N. B., Essex, M. N., Mancuso, J. P., Zhao, Y., & Cherney, D. Z. I. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15895 · Cited by 13
“19 SGLT2 inhibitors have also been shown to lower UA levels and the incidence of gout episodes in persons with T2D, potentially extending the application of these agents as anti-gout therapies beyond their cardiovascular and kidney benefits.”
InfluentialSelf-citationCao, M.-J., Liang, T., Xu, L., & Shi, F. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01547-x · Cited by 11
Siriwardana, A. N., Buizen, L., Jun, M., Kotwal, S. S., Arnott, C. G., Jardine, M., Levin, A., Heerspink, H. J. L., Charytan, D. M., Pollock, C. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16190 · Cited by 9
Lee, S. W., Park, H., Lee, M. Y., Lee, H., & Kang, E. S. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2223 · Cited by 9
Wang, W., Tang, W., Webster‐Clark, M., Yu, O. H. Y., & Filion, K. B. (2025) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2025.111872 · Cited by 9
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
“The evidence base for hematologic cancer origins was limited to a single RCT [103], which prevented meaningful NMA for the subgroup analysis.”
Inoue, D., Nishi, H., Inoue, R., & Nangaku, M. (2021) · International Heart Journal · doi:10.1536/ihj.20-716 · Cited by 10
Chen, C., Peng, H., Li, M., Lu, X., Huang, M., Zeng, Y., & Dong, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.664533 · Cited by 10
Song, Z., Wang, X., Wang, X., Liu, J., Luo, S.-Q., Xu, S.-S., Xiao, C., Bai, J., Dong, L., Zhang, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.900114 · Cited by 10
Oyama, K., Raz, I., Cahn, A., Goodrich, E. L., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Gause‐Nilsson, I. A. M., Mosenzon, O., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2006 · Cited by 13
Self-citationA Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes
Cowart, K., Coon, S. A., & Carris, N. W. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231190443 · Cited by 11
Chen, J., Chang, J., Shi, Q., Li, X., Wang, L., & Zhao, H. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03542-y · Cited by 9
“Several cardiovascular outcome trials (CVOTs) [16–19] have demonstrated that SGLT-2i provides additional cardiovascular benefits in patients with T2DM who have multiple risk factors for atherosclerotic cardiovascular disease or established atherosclerotic cardiovascular disease.”
BackgroundSingh, A. K., Misra, A., Das, A. K., Behl, A., Srivastava, A., Paneerselvam, A., Chidambaram, B., Saboo, B., Sethi, B. K., Makkar, B. M., et al. (2023) · Journal of the Association of Physicians of India · doi:10.59556/japi.71.0422 · Cited by 12
Pescariu, S. A., Elagez, A., Nallapati, B., Bratosin, F., Bucur, A., Negru, A. G., Gaiţă, L., Citu, I. M., Popa, Z. L., & Barata, P. I. (2024) · Pharmaceuticals · doi:10.3390/ph17070929 · Cited by 10
Value of the triglyceride–glucose index and related parameters in heart failure patients
Fang, Y., Shen, J., & Lyu, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1397907 · Cited by 11
Wang, F., Li, C., Cui, L., Gu, S., Zhao, J., & Wang, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1436217 · Cited by 11
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
Арманович, А. А., Sheibani, M., Трофименко, А. И., Lysov, E. E., Khamidova, F. M., Aznauryan, A., Sukiasyan, L. M., Sahakyan, K., Gevorgyan, T. R., Tatoyan, M. R., et al. (2024) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2024-9-4-126-135 · Cited by 10
Patoulias, D., Papadopoulos, C. E., & Doumas, M. N. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.12.012 · Cited by 9
Wang, S., Wu, T., Zuo, Z., Jin, P., Luo, X., & Deng, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab099 · Cited by 9
Ghosal, S., & Sinha, B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109824 · Cited by 9
Seo, B., Su, J., & Song, Y. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03327-w · Cited by 9
Progress in the management of patients with diabetes and chronic kidney disease
Garcia, L. P., Thomas, S. S., Rajesh, H., & Navaneethan, S. D. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000811 · Cited by 10
“In contrast to the aforementioned SGLT-2i trials, VERTIS CV [21] demonstrated noninferiority of ertugliflozin versus placebo for the standard primary outcome of a major adverse cardiovascular event (MACE) with a trend for a benefit for the key”
ResultKhadanga, S., Barrett, K. V., Sheahan, K. H., & Savage, P. D. (2022) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000761 · Cited by 11
Chandrakumar, H. P., Chillumuntala, S., Singh, G., & McFarlane, S. I. (2021) · Cureus · doi:10.7759/cureus.15533 · Cited by 10
“Ertugliflozin is a much newer agent with around 20 cases of eu-DKA reported in the literature, including the Vertis CV trial [8-11].”
BackgroundInteraction between sodium-glucose co-transporter 2 and the sympathetic nervous system
Azzam, O., Matthews, V. B., & Schlaich, M. P. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000767 · Cited by 10
Botana, M., Escalada, J., Merchante, Á., Reyes‐García, R., & Rozas, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01277-1 · Cited by 11
“0% of participants had macroalbuminuria [6].”
Zimerman, A., Forno, A. D., Rohde, L. E. P., Ternes, C. M. P., Alves, F. D., Decker, S. R. R., da Silveira, A. D., Damiani, L. P., Filho, M. M., Costa, R. S., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.06.002 · Cited by 9
Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis
Li, P., Chen, W., Chen, R., Zhang, H., Yu, Z., Yan, H., Du, B., & Yang, P. C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1558367 · Cited by 8
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis
Ceasovschih, A., Balta, A., Aldeen, E. S., Bianconi, V., Barkas, F., Şener, Y. Z., Jakubová, M., Yılmaz, M. B., Banach, M., Șorodoc, L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101061 · Cited by 12
“Conversely, in VERTIS CV, which evaluated T2DM patients with ASCVD, no significant reduction in MACE or CV death was indicated [91].”
Cosentino, N., Trombara, F., Metrio, M. D., Molinari, C., Genovese, S., Pontone, G., & Marenzi, G. (2025) · Pharmaceuticals · doi:10.3390/ph18081202 · Cited by 8
Lin, P., Zeng, B., Hsu, C., Suen, M., Hung, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · Biomolecules · doi:10.3390/biom15111622 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Reassessing Revascularization Strategies in Coronary Artery Disease and Type 2 Diabetes Mellitus
Liang, B., He, X., & Gu, N. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.738620 · Cited by 8
Yoshikawa, T. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.008 · Cited by 10
Morillas, H., Galcerá, E., Alania-Torres, E., Seller, J., Larumbe, A., Núñez, J. E., & Valle, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304139 · Cited by 9
Alkabbani, W., & Gamble, J. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.11.002 · Cited by 9
Ji, L., Mishra, M., & Geest, B. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041092 · Cited by 9
“The EMPA-REG OUTCOME and VERTIS-CV studies exclusively recruited patients with established cardiovascular disease, while the CANVAS and DECLARE-TIMI 58 trials extended the population to those with cardiovascular risk factors for cardiovascular disease.”
InfluentialAmbulatory Resistant Hypertension and Risk of Heart Failure in the Elderly
Coccina, F., Pierdomenico, A. M., Cuccurullo, C., Pizzicannella, J., Trubiani, O., & Pierdomenico, S. D. (2023) · Diagnostics · doi:10.3390/diagnostics13091631 · Cited by 9
Abdelhamid, M., Alghalayini, K. W., Alhumood, K. A., Altun, B., Arafah, M., Bader, F. M., Ibrahim, M. F., Sabbour, H. M., Shawky, A., Skouri, H. N., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14456 · Cited by 10
The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins
Bodnar, P., Mazurkiewicz, M., Chwalba, T., Romuk, E. B., Ciszek-Chwalba, A., Jacheć, W., & Wojciechowska, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082236 · Cited by 12
“There appears to be a consistent class effect in relation to a reduction in hospitalizations for heart failure [134].”
BackgroundEmerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
Behrooz, L., Lenneman, C. G., & Hamburg, N. M. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01961-z · Cited by 9
Brockmeyer, M., Parco, C., Vargas, K. G., Westenfeld, R., Jung, C., Kelm, M., Roden, M., Akbulut, C., Schlesinger, S., Wolff, G., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-023-01858-8 · Cited by 9
“…investigated GLP-1 receptor agonists (AMPLITUDE-O [41], LEADER [42, 43], and REWIND [44, 45]), nine SGLT2 inhibitors (CANVAS [46], CRE-DENCE [47], DAPA-CKD [48], DECLARE-TIMI 58 [49], EMPA-KIDNEY [50], EMPA-REG [51, 52], EMPEROR-PRESERVED [15, 53], EMPEROR-REDUCED [12, 53], and VERTIS-CV [54]).”
BackgroundInfluentialTan, J., Yang, Y., Wang, J., Wang, Y., Lv, T., Shu, Y., Xu, W., & Chong, L. (2024) · BioScience Trends · doi:10.5582/bst.2024.01006 · Cited by 8
Gherbon, A., Frandeș, M., Dîrpeş, D., Timar, R. Z., & Timar, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01326-8 · Cited by 9
“…cardio-vascular (CV) outcomes trials (CVOTs): EMPA-REG OUTCOME (empagliflozin) [32], CANVAS program, which comprised two randomized, double-blind, placebo-controlled phase 3 trials: CANVAS and CANVAS-R (canagliflozin) [33], DECLARE-TIMI 58 (dapagliflozin) [34], and VER-TIS CV (ertugliflozin) [35].”
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Nikolaidou, A., Ventoulis, I., Karakoulidis, G., Anastasiou, V., Daios, S., Papadopoulos, S.-F., Didagelos, M., Parissis, J., Karamitsos, T. D., Kotsa, K., et al. (2024) · Medicina · doi:10.3390/medicina60060912 · Cited by 10
“After a 3.5-year follow-up, ertugliflozin indicated a 30% lower risk of HF hospitalization but a neutral effect on 3P-MACE and its components, in patients with T2DM and established CVD [103].”
BackgroundInfluentialThe challenge of choosing in cardiovascular risk management
Hoogeveen, R. M., Hanssen, N. M. J., Brouwer, J., Mosterd, A., Tack, C. J., Kroon, A. A., de Borst, G. J., ten Berg, J. M., Trier, T. J. V., van Lennep, J. E. R., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01599-y · Cited by 11
The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
Fadiran, O., & Nwabuo, C. C. (2021) · Cureus · doi:10.7759/cureus.19379 · Cited by 10
“The VERTIS CV trial, which was highly powered to investigate ertugliflozin in 8238 patients with type 2 diabetes and ASCVD, yielded non-inferior outcomes of MACE and CV death or HF hospitalizations [16].”
MethodChalmoukou, K., Polyzos, D., Manta, E., Tatakis, F., Konstantinidis, D., Thomopoulos, C., & Costas, T. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.12.018 · Cited by 10
Garnica-Cuéllar, J. C., Lavalle-González, F. J., Magaña-Serrano, J. A., Almeda-Valdés, P., Canto, J. A. C., Chávez-Iñiguez, J. S., Garza-García, C. A., González-Chávez, A., González-Gálvez, G., Medina-Chávez, J. H., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000596 · Cited by 15
Schechter, M., Fischer, M., & Mosenzon, O. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14675 · Cited by 8
Lioudaki, E., Joslin, J. R., Trachanatzi, E., & Androulakis, E. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303082 · Cited by 10
“patients with type 2 diabetes only [7,9,10,22] but not in others [4,5] and has not been noted in any non-diabetic populations.”
BackgroundResultInfluentialZhao, Z., Jin, P., Zhang, Y., Hu, X. Y., Tian, C., & Liu, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.826684 · Cited by 10
Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.05.005 · Cited by 8
Liang, B., Liang, Y., & Gu, N. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02693-8 · Cited by 9
“Discussion With the release of PRESERVED-HF [13], CANVAS [14], CHIEF-HF [15], and VERTIS CV [16], SGLT2is seem a potential promising therapy for patients with HFpEF.”
BackgroundExtra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 12
“comes Trial (VERTIS-CV) trial randomized 8246 T1DM patients with CVD to ertugliflozin versus placebo; ertugliflozin treatment was noninferior, but failed to show superiority, for the three-point MACE primary outcome [34].”
MethodAl‐Salameh, A., Bouzegaoui, N. E., & Saraval, M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.09.023 · Cited by 14
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction
Rastogi, T., & Girerd, N. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.006 · Cited by 9
Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations
Davidson, J. A., Sukor, N., Hew, F., Mohamed, M., & Hussein, Z. B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13915 · Cited by 9
Hasan, M. T., Awad, A. K., Shih, M., Attia, A. N., Aboeldahab, H. A., Bendary, M. M., & Bendary, A. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.027 · Cited by 9
Brust-Sisti, L. A., Rudawsky, N., Gonzalez, J., & Brunetti, L. (2022) · Pharmacy · doi:10.3390/pharmacy10060166 · Cited by 10
“Canagliflozin and ertugliflozin also sought to evaluate cardiovascular outcomes in patients with T2DM and cardiovascular disease or risk factors via the CANVAS trial and VERTIS-CV trial, respectively [5,6].”
BackgroundMethodAntihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)
Clodi, M., Abrahamian, H., Brath, H., Schernthaner, G., Brix, J., Ludvik, B. H., Drexel, H., Saely, C. H., Fasching, P., Rega‐Kaun, G., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02186-4 · Cited by 9
Kılıçkap, M., Kozluca, V., Tan, T. S., & Akbulut, İ. M. (2023) · Angiology · doi:10.1177/00033197231183229 · Cited by 12
Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
Dadwani, R. S., Wan, W., Skandari, M. R., & Huang, E. S. (2023) · MDM Policy & Practice · doi:10.1177/23814683231187566 · Cited by 8
Patoulias, D., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14297 · Cited by 8
van Raalte, D. H., Bjornstad, P., Heerspink, H. J. L., Persson, F., & Cherney, D. Z. I. (2021) · Kidney International · doi:10.1016/j.kint.2020.12.006 · Cited by 8
Self-citationMarx, N., & Müller‐Wieland, D. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad282 · Cited by 8
Duan, X., Zhang, X., & Sun, B. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02750-4 · Cited by 8
Eom, Y. R., Joo, H., Chae, S. E., & Je, N. K. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70183 · Cited by 8
Contemporary management of advanced chronic kidney disease: An evidence-based review
Baker, L. W., Ovincy, C., Souvalian, L., Hickson, L. J., & Chebib, F. T. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106557 · Cited by 9
Wang, L., Wei, C., Chen, Y., Lu, D.-S., Zhang, H.-X., & Yang, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1673159 · Cited by 11
Metabolic reprogramming in fibrosis-related diseases: underlying mechanisms and therapeutics
Feng, Y., Zhang, X., Wang, X., & Chen, C. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00490-9 · Cited by 7
“Over a mean follow-up of 3.5 years, the study demonstrated that ertugliflozin was not inferior to the placebo in terms of the risk of major adverse cardiovascular events [225].”
InfluentialBeneficial cardiovascular and remodeling effects of SGLT 2 inhibitors
Chrysant, S. G., & Chrysant, G. S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2057949 · Cited by 8
“Cana = canagliflozin, Dapa = dapagliflozin, Empa = empagliflozin, Ertu = ertugliflozin, CVM = cardiovascular mortality, NIMI = nonschemic MI, nonfatal MI, nonfatal stroke, CVM = cardiovascular mortality, CVD = cardiovascular disease, ACM = all-cause mortality, FMI = fatal myocardial infarction, NFMI = nonfatal myocard…”
BackgroundInfluentialDu, L., Qin, J., Wang, D., Zhao, Y., Xu, N., Wu, C., & Yuan, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1028486 · Cited by 7
“We included a total of nine studies (Clegg et al., 2019; Arnott et al., 2020; Cannon et al., 2020; Bhatt et al., 2021a; Bhatt et al., 2021b; Cahn et al., 2021; Dave et al., 2021; Lam et al., 2022; Lopez et al., 2022) in this meta-analysis.”
BackgroundAlogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes
Layman, S. N., Elliott, W. V., Neu, D. W., Howard, T. G., & Hamby, A. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221135656 · Cited by 7
Bose, D., Maurya, M. R., & Konwar, M. (2023) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_342_21 · Cited by 9
“[24,27] Implication of the result ESRD often leads to significant lowering of quality of life.”
Jhund, P. S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15171 · Cited by 8
“The final trial conducted in patients with type 2 diabetes and established CV disease was the VERTIS-CV trial with ertugliflozin.(5) In 8246 patients”
MethodGhosal, S., & Sinha, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168755 · Cited by 7
“P MACE in four trials (EMPAREG, DECLARE TIMI-58, VERTIS-CV, and CANVAS).”
InfluentialHua, T., Chu, Y., Wang, M., Zhang, Y., Shi, W., Huang, Q., Zhang, L., & Yang, M. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00562-y · Cited by 8
Khayari, A. E., Hakam, S. M., Malka, G., Rochette, L., & Fatimy, R. E. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101174 · Cited by 8
Wang, Y., & Zhou, X. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03631-7 · Cited by 7
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
“Growing evidence has shown the protective effect of SGLT2 inhibitors (SGLTis) on cardiovascular, renal, and mortality events in patients with 159 – 163 and without type 2 diabetes 164 – 168 .”
BackgroundFelix, N. S., Gauza, M. D. M., Teixeira, L., Guisso, M. E. S., Nogueira, A., Dagostin, C. S., Godoi, A., Ribeiro, S. A. G., Duque, J. C., Moura-Neto, J. A., et al. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2023.0241 · Cited by 9
Zhu, J., Wilding, J. P. H., & Gu, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2135 · Cited by 9
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Zhang, Y., Liao, X., Xu, J., Yin, J., Li, S., Li, M., Shi, X., Zhang, S., Li, C., Xu, W., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122783 · Cited by 7
Scheen, A. J. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.001 · Cited by 8
Pagidipati, N. J., & DEEDWANIA, P. C. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.04.024 · Cited by 7
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.